Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned a consensus rating of “Hold” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $31.8333.

STRO has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. HC Wainwright upped their price objective on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Wedbush restated a “neutral” rating and issued a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of STRO. State of Tennessee Department of Treasury acquired a new position in shares of Sutro Biopharma during the 4th quarter worth $86,000. Jane Street Group LLC acquired a new stake in Sutro Biopharma in the fourth quarter valued at about $265,000. Catalyst Funds Management Pty Ltd bought a new position in Sutro Biopharma in the second quarter valued at about $27,000. Bridgeway Capital Management LLC grew its position in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Savant Capital LLC acquired a new position in Sutro Biopharma during the second quarter worth about $37,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

NASDAQ:STRO opened at $18.42 on Friday. Sutro Biopharma has a one year low of $5.23 and a one year high of $19.90. The company has a market cap of $156.75 million, a P/E ratio of -0.71 and a beta of 1.55. The firm’s fifty day moving average price is $13.43 and its two-hundred day moving average price is $10.58.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.